DD149526A5 - Verfahren zur herstellung von(+)-(3-methyl-4-oxo-5-n-piperidino-thiazolidin-2-yliden)-essigsaeureestern - Google Patents

Verfahren zur herstellung von(+)-(3-methyl-4-oxo-5-n-piperidino-thiazolidin-2-yliden)-essigsaeureestern Download PDF

Info

Publication number: DD149526A5
Authority: DD; German Democratic Republic
Prior art keywords: ylidene; oxo; methyl; piperidino; thiazolidin
Prior art date: 1979-03-22

Application number

DD80219804A

Other languages

German (de)

English (en)

Inventor

Wolfgang Herrmann

Gerhard Satzinger

Manfred Herrmann

Wolfgang Steinbrecher

Heinrich Bahrmann

Original Assignee

Goedecke Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1979-03-22

Filing date

1980-03-21

Publication date

1981-07-15

1979-03-22 Priority claimed from DE2911296A external-priority patent/DE2911296C2/de

1979-12-29 Priority claimed from DE19792952704 external-priority patent/DE2952704C2/de

1980-03-21 Application filed by Goedecke Ag filed Critical Goedecke Ag

1981-07-15 Publication of DD149526A5 publication Critical patent/DD149526A5/de

Links

150000002168 ethanoic acid esters Chemical class 0.000 title description 2
238000004519 manufacturing process Methods 0.000 title 1
150000001875 compounds Chemical class 0.000 claims abstract description 21
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 claims abstract description 20
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 16
238000000034 method Methods 0.000 claims abstract description 16
238000006243 chemical reaction Methods 0.000 claims abstract description 9
XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 claims abstract description 8
238000002360 preparation method Methods 0.000 claims abstract description 7
UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 claims abstract description 6
230000006340 racemization Effects 0.000 claims abstract description 6
239000012442 inert solvent Substances 0.000 claims abstract description 3
230000035484 reaction time Effects 0.000 claims abstract description 3
239000000203 mixture Substances 0.000 claims description 10
239000002904 solvent Substances 0.000 claims description 5
238000001816 cooling Methods 0.000 claims description 4
125000004432 carbon atom Chemical group C* 0.000 claims description 3
239000000010 aprotic solvent Substances 0.000 claims description 2
150000008280 chlorinated hydrocarbons Chemical class 0.000 claims description 2
239000002934 diuretic Substances 0.000 abstract description 14
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 abstract description 12
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 abstract description 10
229940030606 diuretics Drugs 0.000 abstract description 8
230000000694 effects Effects 0.000 abstract description 7
FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 abstract description 6
239000002220 antihypertensive agent Substances 0.000 abstract description 4
239000007858 starting material Substances 0.000 abstract description 2
NQFBZYYUAFJYNS-FPLPWBNLSA-N (2z)-2-(3-methyl-4-oxo-5-piperidin-1-yl-1,3-thiazolidin-2-ylidene)acetic acid Chemical compound S1\C(=C/C(O)=O)N(C)C(=O)C1N1CCCCC1 NQFBZYYUAFJYNS-FPLPWBNLSA-N 0.000 abstract 1
229940030600 antihypertensive agent Drugs 0.000 abstract 1
239000007795 chemical reaction product Substances 0.000 abstract 1
150000004702 methyl esters Chemical class 0.000 abstract 1
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 27
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 22
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
241001465754 Metazoa Species 0.000 description 10
230000003276 anti-hypertensive effect Effects 0.000 description 10
230000001882 diuretic effect Effects 0.000 description 10
241000700159 Rattus Species 0.000 description 7
229960004514 etozolin Drugs 0.000 description 7
ZCKKHYXUQFTBIK-KTKRTIGZSA-N etozoline Chemical compound O=C1N(C)C(=C/C(=O)OCC)/SC1N1CCCCC1 ZCKKHYXUQFTBIK-KTKRTIGZSA-N 0.000 description 7
239000000243 solution Substances 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
238000012360 testing method Methods 0.000 description 6
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 5
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 5
235000011114 ammonium hydroxide Nutrition 0.000 description 5
230000037396 body weight Effects 0.000 description 5
230000032050 esterification Effects 0.000 description 5
238000005886 esterification reaction Methods 0.000 description 5
239000012071 phase Substances 0.000 description 5
238000003756 stirring Methods 0.000 description 5
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
206010020772 Hypertension Diseases 0.000 description 4
208000004880 Polyuria Diseases 0.000 description 4
239000013078 crystal Substances 0.000 description 4
239000003208 petroleum Substances 0.000 description 4
230000000144 pharmacologic effect Effects 0.000 description 4
230000003389 potentiating effect Effects 0.000 description 4
239000000126 substance Substances 0.000 description 4
-1 6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine Chemical compound 0.000 description 3
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
239000002253 acid Substances 0.000 description 3
229910021529 ammonia Inorganic materials 0.000 description 3
150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000003814 drug Substances 0.000 description 3
GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 3
239000007788 liquid Substances 0.000 description 3
229910052943 magnesium sulfate Inorganic materials 0.000 description 3
235000019341 magnesium sulphate Nutrition 0.000 description 3
229910052938 sodium sulfate Inorganic materials 0.000 description 3
235000011152 sodium sulphate Nutrition 0.000 description 3
239000007787 solid Substances 0.000 description 3
229940126062 Compound A Drugs 0.000 description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 2
201000003099 Renovascular Hypertension Diseases 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 description 2
239000000654 additive Substances 0.000 description 2
238000010171 animal model Methods 0.000 description 2
230000035619 diuresis Effects 0.000 description 2
239000003792 electrolyte Substances 0.000 description 2
230000007717 exclusion Effects 0.000 description 2
229920006158 high molecular weight polymer Polymers 0.000 description 2
238000011835 investigation Methods 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
239000012074 organic phase Substances 0.000 description 2
230000000894 saliuretic effect Effects 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
YONLFQNRGZXBBF-KBPBESRZSA-N (2s,3s)-2,3-dibenzoyloxybutanedioic acid Chemical compound O([C@H](C(=O)O)[C@H](OC(=O)C=1C=CC=CC=1)C(O)=O)C(=O)C1=CC=CC=C1 YONLFQNRGZXBBF-KBPBESRZSA-N 0.000 description 1
SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
241000736839 Chara Species 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Natural products CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
241000206672 Gelidium Species 0.000 description 1
206010018873 Haemoconcentration Diseases 0.000 description 1
206010022998 Irritability Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
241000282376 Panthera tigris Species 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000007059 acute toxicity Effects 0.000 description 1
231100000403 acute toxicity Toxicity 0.000 description 1
235000010419 agar Nutrition 0.000 description 1
125000005907 alkyl ester group Chemical group 0.000 description 1
125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
229940127088 antihypertensive drug Drugs 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
238000009530 blood pressure measurement Methods 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000001364 causal effect Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
239000008139 complexing agent Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
238000002651 drug therapy Methods 0.000 description 1
229960001484 edetic acid Drugs 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
AVOLMBLBETYQHX-UHFFFAOYSA-N etacrynic acid Chemical compound CCC(=C)C(=O)C1=CC=C(OCC(O)=O)C(Cl)=C1Cl AVOLMBLBETYQHX-UHFFFAOYSA-N 0.000 description 1
229960003199 etacrynic acid Drugs 0.000 description 1
ZCKKHYXUQFTBIK-XPSMFNQNSA-N ethyl (2z)-2-[(5s)-3-methyl-4-oxo-5-piperidin-1-yl-1,3-thiazolidin-2-ylidene]acetate Chemical compound O=C1N(C)C(=C/C(=O)OCC)/S[C@@H]1N1CCCCC1 ZCKKHYXUQFTBIK-XPSMFNQNSA-N 0.000 description 1
125000004494 ethyl ester group Chemical group 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
230000029142 excretion Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
229960003883 furosemide Drugs 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
229960002003 hydrochlorothiazide Drugs 0.000 description 1
230000001631 hypertensive effect Effects 0.000 description 1
239000005457 ice water Substances 0.000 description 1
239000012535 impurity Substances 0.000 description 1
GJRQTCIYDGXPES-UHFFFAOYSA-N iso-butyl acetate Natural products CC(C)COC(C)=O GJRQTCIYDGXPES-UHFFFAOYSA-N 0.000 description 1
FGKJLKRYENPLQH-UHFFFAOYSA-M isocaproate Chemical compound CC(C)CCC([O-])=O FGKJLKRYENPLQH-UHFFFAOYSA-M 0.000 description 1
JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 1
229940011051 isopropyl acetate Drugs 0.000 description 1
GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
OQAGVSWESNCJJT-UHFFFAOYSA-N isovaleric acid methyl ester Natural products COC(=O)CC(C)C OQAGVSWESNCJJT-UHFFFAOYSA-N 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
239000008101 lactose Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
231100000053 low toxicity Toxicity 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
YKYONYBAUNKHLG-UHFFFAOYSA-N n-Propyl acetate Natural products CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
238000005580 one pot reaction Methods 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
239000002798 polar solvent Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229940090181 propyl acetate Drugs 0.000 description 1
LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
210000002254 renal artery Anatomy 0.000 description 1
230000000630 rising effect Effects 0.000 description 1
239000000523 sample Substances 0.000 description 1
238000000926 separation method Methods 0.000 description 1
229910052709 silver Inorganic materials 0.000 description 1
239000004332 silver Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
229940124530 sulfonamide Drugs 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
WMOVHXAZOJBABW-UHFFFAOYSA-N tert-butyl acetate Chemical compound CC(=O)OC(C)(C)C WMOVHXAZOJBABW-UHFFFAOYSA-N 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
229960001288 triamterene Drugs 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
235000019871 vegetable fat Nutrition 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Cardiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Heart & Thoracic Surgery (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

DD80219804A 1979-03-22 1980-03-21 Verfahren zur herstellung von(+)-(3-methyl-4-oxo-5-n-piperidino-thiazolidin-2-yliden)-essigsaeureestern DD149526A5 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE2911296A DE2911296C2 (de)	1979-03-22	1979-03-22	(+)-(3-Methyl-4-oxo-5- piperidinothiazolidin-2-yliden)-essigsäureester, Verfahren zu deren Herstellung und deren Verwendung bei der Bekämpfung der Hypertonie
DE19792952704 DE2952704C2 (de)	1979-12-29	1979-12-29	Verfahren zur Herstellung von (+)-(3-Methyl-4-oxo-5-piperidino-thiazolidin-2-yliden)-essigsäureestern

Publications (1)

Publication Number	Publication Date
DD149526A5 true DD149526A5 (de)	1981-07-15

Family

ID=25778343

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DD80219804A DD149526A5 (de)	1979-03-22	1980-03-21	Verfahren zur herstellung von(+)-(3-methyl-4-oxo-5-n-piperidino-thiazolidin-2-yliden)-essigsaeureestern

Country Status (14)

Country	Link
US (1)	US4255433A (da)
EP (1)	EP0016635B1 (da)
AU (1)	AU531659B2 (da)
DD (1)	DD149526A5 (da)
DE (1)	DE3061727D1 (da)
DK (1)	DK120980A (da)
ES (1)	ES489777A1 (da)
FI (1)	FI70711C (da)
HU (1)	HU182110B (da)
IE (1)	IE49651B1 (da)
PH (1)	PH15767A (da)
PL (1)	PL124396B1 (da)
SU (1)	SU884571A3 (da)
YU (1)	YU77180A (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4088789A (en) *	1973-07-11	1978-05-09	Plate Bonn Gesellshaft Mit Beschrankter Haftung	Ensilaging agent for fodder plants
DE3739779A1 (de) *	1987-11-24	1989-06-08	Beiersdorf Ag	Pharmazeutische praeparate

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3072653A (en) *	1961-03-06	1963-01-08	Warner Lamber Pharmaceutical C	5-amino derivatives of 4-thiazolidinones and process therefor
US4012395A (en) *	1974-03-25	1977-03-15	Warner-Lambert Company	Process for preparing thiazolidinone acetic acid derivatives
DE2414345C3 (de) *	1974-03-25	1980-02-21	Goedecke Ag, 1000 Berlin	(Z)-(3-Methyl-4-oxo-5-piperidinothiazolidin-2-yIiden)-esssigsäure und Verfahren zur Herstellung von Thiazolidinessigsäure-Derivaten
DE2532180C2 (de) *	1975-07-18	1986-12-18	Gödecke AG, 1000 Berlin	Verwendung von Etozolin bei der Bekämpfung der Hypertonie
DE2658858A1 (de) *	1976-12-24	1978-06-29	Goedecke Ag	(-)-(3-methyl-4-oxo-5-n-piperidino- thiazolidin-2-yliden-)essigsaeure

1980
- 1980-03-14 AU AU56460/80A patent/AU531659B2/en not_active Ceased
- 1980-03-19 DE DE8080300834T patent/DE3061727D1/de not_active Expired
- 1980-03-19 EP EP80300834A patent/EP0016635B1/en not_active Expired
- 1980-03-19 PH PH23786A patent/PH15767A/en unknown
- 1980-03-20 DK DK120980A patent/DK120980A/da not_active Application Discontinuation
- 1980-03-20 YU YU00771/80A patent/YU77180A/xx unknown
- 1980-03-21 ES ES489777A patent/ES489777A1/es not_active Expired
- 1980-03-21 US US06/132,577 patent/US4255433A/en not_active Expired - Lifetime
- 1980-03-21 DD DD80219804A patent/DD149526A5/de unknown
- 1980-03-21 IE IE588/80A patent/IE49651B1/en unknown
- 1980-03-21 FI FI800897A patent/FI70711C/fi not_active IP Right Cessation
- 1980-03-21 HU HU80682A patent/HU182110B/hu unknown
- 1980-03-21 SU SU802896599A patent/SU884571A3/ru active
- 1980-03-22 PL PL1980222925A patent/PL124396B1/pl unknown

Also Published As

Publication number	Publication date
PL124396B1 (en)	1983-01-31
IE49651B1 (en)	1985-11-13
IE800588L (en)	1980-09-22
SU884571A3 (ru)	1981-11-23
US4255433A (en)	1981-03-10
PL222925A1 (da)	1981-01-30
PH15767A (en)	1983-03-24
FI70711C (fi)	1986-10-06
EP0016635B1 (en)	1983-01-26
ES489777A1 (es)	1980-09-16
FI70711B (fi)	1986-06-26
EP0016635A1 (en)	1980-10-01
DE3061727D1 (en)	1983-03-03
AU531659B2 (en)	1983-09-01
DK120980A (da)	1980-09-23
FI800897A7 (fi)	1980-09-23
AU5646080A (en)	1980-09-25
YU77180A (en)	1984-04-30
HU182110B (en)	1983-12-28

Publication	Publication Date	Title
DE1620024C3 (de)	1974-07-25	3'-Pyridylmethyl-2-(4-chlorphenoxy)-2-methylpropionat
DE2508895A1 (de)	1975-09-18	Salze von phenylalkancarbonsaeuren mit basischen aminosaeuren
DE2203373A1 (de)	1972-08-17	Neue Imidazolinderivate,Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Praeparate
DE2653257C2 (da)	1989-04-20
DD149526A5 (de)	1981-07-15	Verfahren zur herstellung von(+)-(3-methyl-4-oxo-5-n-piperidino-thiazolidin-2-yliden)-essigsaeureestern
DE1932389B2 (de)	1974-03-07	Neue 2-Naphthyl-2-methyläthanole und deren Acetate, sie enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE2746550C2 (da)	1987-10-15
DE1695812C3 (de)	1980-10-16	Dibenzo [c,f] -1,2-thiazepin-derivate, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zubereitung
DE2446100B2 (de)	1981-01-15	Phenoxyalkancarbonsäureamide von Thiazolidincarbonsäuren, Verfahren zu ihrer Herstellung und Arzneimittel
DE2911296C2 (de)	1981-07-30	(+)-(3-Methyl-4-oxo-5- piperidinothiazolidin-2-yliden)-essigsäureester, Verfahren zu deren Herstellung und deren Verwendung bei der Bekämpfung der Hypertonie
DE2736268A1 (de)	1978-02-16	Neue 5-thiazolalkylamin-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen
DE2640430A1 (de)	1977-03-31	Arzneimittel zur erhoehung der harnsaeuresekretion
DE2128887A1 (de)	1971-12-16	Derivate der beta eckige Klammer auf Benzo (b) thienyl 3 eckige Klammer zu propionsäure, deren Herstellung und die selben enthaltende Arzneimittel
DE3586150T2 (de)	1993-01-14	Amidderivate der 2-(p-aminobenzyl)-buttersaeure und ihrer ester mit blutfettgehaltsenkender wirkung.
DE2414345C3 (de)	1980-02-21	(Z)-(3-Methyl-4-oxo-5-piperidinothiazolidin-2-yIiden)-esssigsäure und Verfahren zur Herstellung von Thiazolidinessigsäure-Derivaten
DE1770250C2 (de)	1974-04-18	l-Cinnamoyl-3-indolylcarbonsäureanhydride, Verfahren zu ihrer Herstellung und Arzneipräparate
DE1518006B2 (da)	1973-10-04
EP0007347A1 (de)	1980-02-06	Lipidsenkende Alkylenglykolderivate und Verfahren zu ihrer Herstellung.
DE2803205A1 (de)	1978-08-03	Das lysinsalz der alpha-methyl-(2- isopropyl-5-indanyl)-essigsaeure, verfahren zu seiner herstellung und pharmazeutische mittel
DE2145686C3 (de)	1978-02-16	2-Chlor-S-sulfamylbenzoesäurederivate, Verfahren zu ihrer Herstellung und Arzneimittel, die diese Verbindungen enthalten
DE2404924A1 (de)	1974-08-22	Ergolinderivate
DE853794C (de)	1952-10-27	Verfahren zur Herstellung von Penicillinverbindungen mit verlaengerter Wirkung
DE2055264C3 (de)	1976-05-20	Thienyl(2) -essigsäurederivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
DE2523208C3 (de)	1977-08-18	Thienylessigsäureester, ein Verfahren zu ihrer Herstellung sowie Arzneimittel
DE2658858A1 (de)	1978-06-29	(-)-(3-methyl-4-oxo-5-n-piperidino- thiazolidin-2-yliden-)essigsaeure